APPLICATION
ANDA079121
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-03
LATEST ACTION
2025-10-09
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued
Products
ESCITALOPRAM OXALATEDiscontinued
ESCITALOPRAM OXALATE EQ 5MG BASE/5ML · SOLUTION · ORAL
Approval history
2025-10-09Labeling · Supplement 14 · standardAP
2024-03-08Labeling · Supplement 13 · standardAP
2021-09-21Labeling · Supplement 11 · standardAP
2021-09-08Labeling · Supplement 8 · standardAP
2021-09-08Labeling · Supplement 10 · standardAP
2021-09-08Labeling · Supplement 9 · standardAP
2014-11-04Labeling · Supplement 6 · standardAP
2013-05-20Labeling · Supplement 1 · standardAP
2013-05-20Labeling · Supplement 2 · standardAP
2012-05-03OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.